A pilot study on ultrashort peptide with fluconazole: A promising novel anticandidal combination

A pilot study on ultrashort peptide with fluconazole: A promising novel anticandidal combination

Human infections caused by are common and range in severity from relatively treatable skin and mucosal conditions to systemic, fatal invasive candidiasis. The treatment of fungal infections is challenged by major obstacles, including the scarcity of effective therapeutic options, the toxicity of ava...

Full description

Saved in:
Bibliographic Details
Published in:Veterinary World Vol. 16; no. 6; pp. 1284 - 1288
Main Authors: Darwish, Rula M, Salama, Ali H
Format: Journal Article
Language:English
Published: India Veterinary World 01-06-2023
Subjects:
candida albicans
Care and treatment
drug combinations
Drug resistance in microorganisms
Drug therapy, Combination
Fluconazole
Health aspects
Infection
Peptides
synergism
ultrashort peptide
Candida albicans
synergism
fluconazole
drug combinations
ultrashort peptide
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Human infections caused by are common and range in severity from relatively treatable skin and mucosal conditions to systemic, fatal invasive candidiasis. The treatment of fungal infections is challenged by major obstacles, including the scarcity of effective therapeutic options, the toxicity of available medications, and the escalating antifungal resistance. Hence, there exists an urgent need to develop new classes of antimicrobial agents. This study was conducted to investigate the effect of KW-23 peptide against standard and resistant strains of alone and in combination with fluconazole. A conjugated ultrashort antimicrobial peptide (KW-23) was designed and synthesized. KW-23 was challenged against standard and multidrug-resistant alone and in combination with fluconazole using standard antimicrobial and checkerboard assays. The toxicity of the peptide was examined using hemolytic assays. KW-23 positively affected the standard and resistant Candidal strains (at 5 and 15 μg/mL respectively), exhibiting potent synergistic antimicrobial activity against the standard strain when combined with fluconazole. The effect of the combination was additive against the resistant strain (0.6 μg/mL). Furthermore, the peptide exhibited negligible toxicity on human erythrocytes. KW-23 and its combination with fluconazole could be a promising candidate for developing anticandidal agents.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0972-8988
2231-0916
DOI:10.14202/vetworld.2023.1284-1288